Mental DailyMental Daily
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • More
    • Opinion
    • The Discussion
    • My Bookmarks
Aa
Mental Daily
Aa
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • Opinion
Search
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • More
    • Opinion
    • The Discussion
    • My Bookmarks
Follow US
  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store
© 2022 - Mental Daily. All Rights Reserved.
Clinical

New research entertains the theory of antidepressant efficacy as early-COVID-19 treatment

Staff Writer
Staff Writer 7 months ago
Updated 2021/10/29 at 1:45 AM
Share
SHARE

A group of researchers has entertained the theory of antidepressant use for early treatment of COVID-19, with potential efficacious outcomes.

In a study published by the Lancet, researchers suggested that the antidepressant drug fluvoxamine may provide some extent of efficacy for the early treatment of COVID-19 among acutely symptomatic patients.

For the study, nearly 10,000 people were screened, as part of a clinical trial that began on June 2nd, 2020. As many as 741 participants were administered fluvoxamine, while the other 756 a placebo.

According to the Lancet study: “This is, to the best of our knowledge, the first large, randomised controlled trial to test the efficacy of fluvoxamine for acute treatment of COVID-19. We found a clinically important absolute risk reduction of 5·0%, and 32% RR reduction, on the primary outcome of hospitalization.”

Recent evidence indicates a potential therapeutic role of fluvoxamine for COVID-19. In the TOGETHER trial for acutely symptomatic patients with COVID-19, we aimed to assess the efficacy of fluvoxamine versus placebo in preventing hospitalisation.”

Photo: Getty Images

You Might Also Like

Type 2 diabetes may lead to a significant increase in brain aging and cognitive decline

Study finds no structural brain change during mindfulness-based stress training

Study finds diet may be a contributing factor in ADHD symptoms associated in children

New research claims COVID-19 contagion may raise the risk of neurodegenerative disorder

ALS experimental drug NU-9 more efficacious than existing FDA-approved drugs

TAGGED: COVID-19, mental health, antidepressants
Staff Writer October 28, 2021
Share this Article
Facebook Twitter Whatsapp Whatsapp Email Print
Previous Article Brisk walking may reduce the severity of symptoms associated with postpartum depression
Next Article Widespread availability of fast food joints may explain the high incidences of type 2 diabetes

Recommended

Clinical

Type 2 diabetes may lead to a significant increase in brain aging and cognitive decline

1 Min Read
Clinical

Study finds no structural brain change during mindfulness-based stress training

1 Min Read
Clinical

Study finds diet may be a contributing factor in ADHD symptoms associated in children

1 Min Read
Clinical

New research claims COVID-19 contagion may raise the risk of neurodegenerative disorder

1 Min Read
//

We are a trusted online source for research news and resources on all aspects of the mind and human behavior.

Verticals

  • Clinical
  • Health
  • Social
  • I/O
  • Opinion

Social

  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store

Links

  • About
  • Contact
  • Terms & Conditions
  • Privacy Policy
Follow US

© 2022 Mental Daily. All Rights Reserved.

  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store

Removed from reading list

Undo
Welcome Back!

Sign in to your account

Lost your password?